MARKET

NGENF

NGENF

Nervgen Pharma Corp
OTCMQB
4.500
+0.140
+3.21%
Closed 15:52 12/18 EST
OPEN
4.350
PREV CLOSE
4.360
HIGH
4.750
LOW
4.350
VOLUME
47.36K
TURNOVER
218.17K
52 WEEK HIGH
5.08
52 WEEK LOW
1.500
MARKET CAP
352.65M
P/E (TTM)
-17.2944
1D
5D
1M
3M
1Y
5Y
1D
NervGen Pharma Files SEC Registration to Advance Strategic Growth
TipRanks · 1d ago
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS
Newsfile · 1d ago
NERVGEN PHARMA CORP FILES FOR MIXED SHELF OF UP TO $150 MLN – SEC FILING
Reuters · 1d ago
Weekly Report: what happened at NGENF last week (1208-1212)?
Weekly Report · 4d ago
NervGen Pharma Proposes Amendment to Warrant Terms
TipRanks · 6d ago
NervGen Pharma Announces Proposed Amendment to Warrants
Newsfile · 6d ago
NERVGEN PHARMA CORP <NGEN.V>: RAYMOND JAMES RAISES TARGET PRICE TO C$8.00 FROM C$6.00
Reuters · 12/11 12:36
CANADA RESEARCH ROUNDUP-BCE, Capital Power, Telus
Reuters · 12/11 12:21
More
About NGENF
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Webull offers NervGen Pharma Corp stock information, including OTCMQB: NGENF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NGENF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NGENF stock methods without spending real money on the virtual paper trading platform.